Literature DB >> 20352599

Etomidate unmasks intraadrenal regulation of steroidogenesis and proliferation in adrenal cortical cell lines.

S Hahner1, A Stürmer, M Fassnacht, R W Hartmann, K Schewe, S Cochran, M Zink, A Schirbel, B Allolio.   

Abstract

To characterize intraadrenal adaptations for inhibition of cortisol synthesis, we analyzed the effects of etomidate (ETO) on steroid hormone secretion and expression of key regulators of steroidogenesis and proliferation in human NCI-h295 adrenocortical cancer cells. Etomidate potently blocked 11beta-hydroxylase (CYP11B1), aldosterone synthase (CYP11B2), and side chain cleavage enzyme (CYP11A1). This inhibition of steroidogenesis was associated with increased expression of steroidogenic acute regulatory protein (StAR), and CYP11A1 and 17alpha-hydroxylase/17, 20-lyase (CYP17A1) protein levels, but not of the respective mRNA levels. Promoter activity of CYP11A1 and melanocortin 2 receptor (MC2R) was not increased by etomidate in treated cells compared to controls. The increase in protein levels was partially reversed by cycloheximide suggesting post-transcriptional mechanisms but also protein stabilization as underlying cause. Furthermore, ETO exhibited antiproliferative activity paralleled by a decrease in phosphorylation of MEK and ERK1, 2. In summary, ETO exhibits pleiotropic effects on adrenal function in vitro. Inhibition of steroidogenesis is followed by increased levels of steroidogenic key proteins and reduced proliferation. These changes reflect adaptations to maintain steroidogenesis at the cost of adrenal proliferation. Georg Thieme Verlag KG Stuttgart * New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20352599     DOI: 10.1055/s-0030-1249629

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  7 in total

Review 1.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

3.  Dimethoxy-etomidate: A Nonhypnotic Etomidate Analog that Potently Inhibits Steroidogenesis.

Authors:  Megan McGrath; Celena Ma; Douglas E Raines
Journal:  J Pharmacol Exp Ther       Date:  2017-12-04       Impact factor: 4.030

4.  Sunitinib Inhibits Cell Proliferation and Alters Steroidogenesis by Down-Regulation of HSD3B2 in Adrenocortical Carcinoma Cells.

Authors:  Matthias Kroiss; Miriam Reuss; Dorothee Kühner; Sarah Johanssen; Melanie Beyer; Martina Zink; Michaela F Hartmann; Vivek Dhir; Stefan A Wudy; Wiebke Arlt; Silviu Sbiera; Bruno Allolio; Martin Fassnacht
Journal:  Front Endocrinol (Lausanne)       Date:  2011-09-09       Impact factor: 5.555

5.  Using Etomidate in a Two-month-old Infant with Cushing Syndrome due to Adrenocortical Carcinoma

Authors:  Ahreum Kwon; Yongha Choi; Jo Won Jung; Junghwan Suh; Ho-Seong Kim
Journal:  J Clin Res Pediatr Endocrinol       Date:  2020-11-30

6.  Combined Use of Etomidate and Dexmedetomidine Produces an Additive Effect in Inhibiting the Secretion of Human Adrenocortical Hormones.

Authors:  Hongbin Gu; Mazhong Zhang; Meihua Cai; Jinfen Liu
Journal:  Med Sci Monit       Date:  2015-11-16

7.  Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature.

Authors:  Agnieszka Łebek-Szatańska; Karolina M Nowak; Wojciech Zgliczyński; Elżbieta Baum; Agnieszka Żyłka; Lucyna Papierska
Journal:  Ther Adv Endocrinol Metab       Date:  2019-02-08       Impact factor: 3.565

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.